Shares in Trainline PLC (LSE:TRN) fell after the ticket booking specialist was on the receiving end of a downgrade by a leading investment bank.
UBS moved to 'neutral' from 'buy' with the Swiss bank saying that while the long-term prospects for the business remain intact, there are "few near-term" catalysts.
Panthera Resources PLC (AIM:PAT) has been highlighted by VSA Capital as one of a growing number of small caps offering potentially significant upside via international litigation.
Indeed, the broker suggests that there is now even a growing sub-sector of litigation stocks or independent companies seeking compensation from foreign governments via International Arbitration afforded under bilateral investment treaties.
JP Morgan has reaffirmed its 'overweight' rating on Shell PLC (LSE:SHEL, NYSE:SHEL), highlighting the company's potential to lead a new phase of efficient energy investments.
Looking at the wider sector, the bank predicts that European oil companies will begin focusing on more specialised low-carbon growth strategies by 2025, balancing near-term performance with long-term sustainability.
Shares in BBaltic Classifieds Group PLC (LSE:BCG) fell 6% after Deutsche Bank downgraded stock in the media group 'hold' from 'buy' despite a strong set of interim results.
The move follows a detailed review of the company’s performance. Revenue rose 17% to €41.8 million, slightly above DB's forecast of €41.4 million. Adjusted EBITDA margin increased to 79%, yielding an EBITDA of €32.9 million, surpassing the bank's projection of €32.2 million.
Centrica PLC (LSE:CNA) will hold an investor 'teach-in' on 10 December to try and highlight the attractions of its nascent smart metering business and some analysts expect the British Gas owner will also provide a trading update on the day.
The FTSE 100 group is expected to hike its outlook for the full year, said UBS, thanks to supportive trends in commodity prices, particularly natural gas, and the company’s improved risk management in trading operations.
On the Beach Group (LSE:OTB) has received a revised price target of 300p, up from 200p, from Panmure Liberum, with the broker reiterating its ‘buy’ recommendation for the travel group’s shares.
The upgrade reflects Panmure’s optimism about the company’s expanding addressable market and robust trading performance.
Is it time to take a contrary view on car makers? Analysts at Deutsche Bank believe so, though investors might need a thick skin.
“Automotive stocks are having a hard time globally. Unfortunately, we believe the industry is likely to head into another year of volatility and headwinds across regions.
Plant hire giant Ashtead Group PLC (LSE:AHT) has copped a downgrade from analysts at Deutsche Bank the day before its latest quarterly update.
Hold from buy is the new recommendation though Deutsche Bank says that Ashtead is the second-largest US equipment rental operator in the US and longer-term prospects are fine.
It has been a stellar year for mid-market retailer Marks and Spencer Group PLC (LSE:MKS), with last week’s decision by deputy prime minister Angela Raynor to overturn a block on M&S’ Marble Arch store development plans the cherry on top.
Raynor’s decision ended a three-year legal dispute brought by former Tory secretary of state for housing Michael Gove, which was today slammed by broker Shore Capital Markets as a “disgraceful episode” representative of the “uselessness of Tory regime”.
Foxtons Plc (LSE:FOXT) edged higher on a bullish write-up on London’s leading estate agency from mid-cap specialist broker Panmure Liberum.
According to the broker, Foxton is delivering significant market share gains, driven “by its systematic sales approach, unique technology platform and strong brand”.
Investment bank Jefferies expects London Stock Exchange Group PLC's (LSE:LSEG) data and feeds business to lead a re-rating of the FTSE 100-listed firm’s share price.
Jefferies analysts estimate that ‘data and feeds’, which comprises real-time and quantitative market data, will contribute 23% worth of top-line growth in the following two years.
If successful, POLB 001 could remove a critical bottleneck in cancer immunotherapy by freeing up hospital beds and allowing more patients to receive treatment in outpatient settings, according to analysts at Shore Capital.
In doing so, it could position the Poolbeg Pharma PLC's (AIM:POLB) lead programme at the centre of a growing market opportunity estimated at $10 billion, they added.